{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"groups":[{"description":"Relapsed or refractory myeloma patients","id":"OG000","title":"AUTO2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who received at least 1 dose (complete or partial) of AUTO2 therapy (infused set)","reportingStatus":"POSTED","timeFrame":"Up to 28 days post-infusion","title":"Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period","type":"PRIMARY","unitOfMeasure":"Participants"}